🇺🇸 FDA
Patent

US 8629119

Dual targeting of MIR-208 and MIR-499 in the treatment of cardiac disorders

granted A61PA61P21/00A61P9/00

Quick answer

US patent 8629119 (Dual targeting of MIR-208 and MIR-499 in the treatment of cardiac disorders) held by The Board of Regents of the University of Texas System expires Mon Jan 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Jan 14 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61P, A61P21/00, A61P9/00, A61P9/04, A61P9/10